肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

CLIN CANCER RES：抑制EphB4-ephrin-B信号可以增强头颈部肿瘤对西妥昔单抗-放疗的治疗反应

2018-09-29 MedSci MedSci原创

头颈部肿瘤EphB4-ephrin-B治疗反应
关注

低反应率和治疗耐药成为西妥昔单抗和放疗（RT）等治疗策略取得临床成功的主要阻碍。CLIN CANCER RES近期发表了一篇文章，研究EphB4-ephrin-B2原癌基因信号在头颈部肿瘤的EGFR抑制和放疗耐药中的作用。

低反应率和治疗耐药成为西妥昔单抗和放疗（RT）等治疗策略取得临床成功的主要阻碍。CLIN CANCER RES近期发表了一篇文章，研究EphB4-ephrin-B2原癌基因信号在头颈部肿瘤的EGFR抑制和放疗耐药中的作用。

作者使用患者来源的头颈部鳞状细胞癌（HNSCC）异种移植（PDX）模型和HNSCC细胞系来验证其假设。对肿瘤组织进行PhosphoRTK和WB检测以研究EphB4-ephrin-B2的变化。分别对PDX肿瘤和HNSCC细胞系进行mRNA测序和芯片数据分析，以明确与肿瘤细胞生长，增殖和存活有关的基因表达的差异。通过MTT实验研究下调EphB4 / ephrin-B2表达对HNSCC细胞生长的影响。研究结果表明，接受标准放化疗治疗的局部晚期HNSCC患者治疗失败后EphB4和ephrin-B2水平升高。EphB4-ephrin-B2抑制可以显着增强对西妥昔单抗和RT的治疗反应，延长小鼠的生存。肿瘤生长的抑制伴随着促增殖分子水平的下调和细胞凋亡的增加。

文章最后认为，采用合理的药物组合可以提高治疗效果。阻断EphB4-ephrin-B可以增强HNSCC对西妥昔单抗-放疗的治疗反应，可能会对这些患者产生临床获益。

原始出处：

Shilpa Bhatia, Jaspreet Sharma,et al. Inhibition of EphB4–Ephrin-B2 Signaling Enhances Response to Cetuximab–Radiation Therapy in Head and Neck Cancers.CLIN CANCER RES.September 2018 doi: 10.1158/1078-0432.CCR-18-0327

本文系梅斯医学（MedSci）原创编译整理，转载需授权！


版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1679448, encodeId=bbac16e94487c, content=<a href='/topic/show?id=d2ea9048398' target=_blank style='color:#2F92EE;'>#西妥昔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90483, encryptionId=d2ea9048398, topicName=西妥昔)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=271a27776763, createdName=chengjn, createdTime=Thu Jan 24 16:28:00 CST 2019, time=2019-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1491832, encodeId=715d14918321b, content=<a href='/topic/show?id=b4f14442346' target=_blank style='color:#2F92EE;'>#头颈部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44423, encryptionId=b4f14442346, topicName=头颈部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b2d8903151, createdName=wshxjq, createdTime=Mon Oct 01 10:28:00 CST 2018, time=2018-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589777, encodeId=cbff1589e774e, content=<a href='/topic/show?id=124d10065220' target=_blank style='color:#2F92EE;'>#颈部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100652, encryptionId=124d10065220, topicName=颈部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c46a17776631, createdName=木头人519, createdTime=Mon Oct 01 10:28:00 CST 2018, time=2018-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=347262, encodeId=f53834e26275, content=放疗技术的改进 现如今放化疗耐药是限制提高局控率降低远转的主要难题 这个基因的发现将有助于耐药机制的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c2ac2452729, createdName=123faa6dm71暂无昵称, createdTime=Sat Sep 29 21:27:47 CST 2018, time=2018-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=347260, encodeId=4fdd34e260db, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4mzqK7XHyH86ToibWNdzamnZozW6yiceXFib4QHq1lCOia34v7bgwXUIH1Rdnoqia2y6ibLX156v1xmicZw/0, createdBy=15891613430, createdName=xuexin53, createdTime=Sat Sep 29 21:11:23 CST 2018, time=2018-09-29, status=1, ipAttribution=)]
    2019-01-24 chengjn

    #西妥昔#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1679448, encodeId=bbac16e94487c, content=<a href='/topic/show?id=d2ea9048398' target=_blank style='color:#2F92EE;'>#西妥昔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90483, encryptionId=d2ea9048398, topicName=西妥昔)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=271a27776763, createdName=chengjn, createdTime=Thu Jan 24 16:28:00 CST 2019, time=2019-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1491832, encodeId=715d14918321b, content=<a href='/topic/show?id=b4f14442346' target=_blank style='color:#2F92EE;'>#头颈部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44423, encryptionId=b4f14442346, topicName=头颈部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b2d8903151, createdName=wshxjq, createdTime=Mon Oct 01 10:28:00 CST 2018, time=2018-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589777, encodeId=cbff1589e774e, content=<a href='/topic/show?id=124d10065220' target=_blank style='color:#2F92EE;'>#颈部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100652, encryptionId=124d10065220, topicName=颈部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c46a17776631, createdName=木头人519, createdTime=Mon Oct 01 10:28:00 CST 2018, time=2018-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=347262, encodeId=f53834e26275, content=放疗技术的改进 现如今放化疗耐药是限制提高局控率降低远转的主要难题 这个基因的发现将有助于耐药机制的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c2ac2452729, createdName=123faa6dm71暂无昵称, createdTime=Sat Sep 29 21:27:47 CST 2018, time=2018-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=347260, encodeId=4fdd34e260db, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4mzqK7XHyH86ToibWNdzamnZozW6yiceXFib4QHq1lCOia34v7bgwXUIH1Rdnoqia2y6ibLX156v1xmicZw/0, createdBy=15891613430, createdName=xuexin53, createdTime=Sat Sep 29 21:11:23 CST 2018, time=2018-09-29, status=1, ipAttribution=)]
    2018-10-01 wshxjq

    #头颈部#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1679448, encodeId=bbac16e94487c, content=<a href='/topic/show?id=d2ea9048398' target=_blank style='color:#2F92EE;'>#西妥昔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90483, encryptionId=d2ea9048398, topicName=西妥昔)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=271a27776763, createdName=chengjn, createdTime=Thu Jan 24 16:28:00 CST 2019, time=2019-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1491832, encodeId=715d14918321b, content=<a href='/topic/show?id=b4f14442346' target=_blank style='color:#2F92EE;'>#头颈部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44423, encryptionId=b4f14442346, topicName=头颈部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b2d8903151, createdName=wshxjq, createdTime=Mon Oct 01 10:28:00 CST 2018, time=2018-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589777, encodeId=cbff1589e774e, content=<a href='/topic/show?id=124d10065220' target=_blank style='color:#2F92EE;'>#颈部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100652, encryptionId=124d10065220, topicName=颈部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c46a17776631, createdName=木头人519, createdTime=Mon Oct 01 10:28:00 CST 2018, time=2018-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=347262, encodeId=f53834e26275, content=放疗技术的改进 现如今放化疗耐药是限制提高局控率降低远转的主要难题 这个基因的发现将有助于耐药机制的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c2ac2452729, createdName=123faa6dm71暂无昵称, createdTime=Sat Sep 29 21:27:47 CST 2018, time=2018-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=347260, encodeId=4fdd34e260db, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4mzqK7XHyH86ToibWNdzamnZozW6yiceXFib4QHq1lCOia34v7bgwXUIH1Rdnoqia2y6ibLX156v1xmicZw/0, createdBy=15891613430, createdName=xuexin53, createdTime=Sat Sep 29 21:11:23 CST 2018, time=2018-09-29, status=1, ipAttribution=)]
    2018-10-01 木头人519

    #颈部#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1679448, encodeId=bbac16e94487c, content=<a href='/topic/show?id=d2ea9048398' target=_blank style='color:#2F92EE;'>#西妥昔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90483, encryptionId=d2ea9048398, topicName=西妥昔)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=271a27776763, createdName=chengjn, createdTime=Thu Jan 24 16:28:00 CST 2019, time=2019-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1491832, encodeId=715d14918321b, content=<a href='/topic/show?id=b4f14442346' target=_blank style='color:#2F92EE;'>#头颈部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44423, encryptionId=b4f14442346, topicName=头颈部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b2d8903151, createdName=wshxjq, createdTime=Mon Oct 01 10:28:00 CST 2018, time=2018-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589777, encodeId=cbff1589e774e, content=<a href='/topic/show?id=124d10065220' target=_blank style='color:#2F92EE;'>#颈部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100652, encryptionId=124d10065220, topicName=颈部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c46a17776631, createdName=木头人519, createdTime=Mon Oct 01 10:28:00 CST 2018, time=2018-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=347262, encodeId=f53834e26275, content=放疗技术的改进 现如今放化疗耐药是限制提高局控率降低远转的主要难题 这个基因的发现将有助于耐药机制的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c2ac2452729, createdName=123faa6dm71暂无昵称, createdTime=Sat Sep 29 21:27:47 CST 2018, time=2018-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=347260, encodeId=4fdd34e260db, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4mzqK7XHyH86ToibWNdzamnZozW6yiceXFib4QHq1lCOia34v7bgwXUIH1Rdnoqia2y6ibLX156v1xmicZw/0, createdBy=15891613430, createdName=xuexin53, createdTime=Sat Sep 29 21:11:23 CST 2018, time=2018-09-29, status=1, ipAttribution=)]
    2018-09-29 123faa6dm71暂无昵称

    放疗技术的改进 现如今放化疗耐药是限制提高局控率降低远转的主要难题 这个基因的发现将有助于耐药机制的研究

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1679448, encodeId=bbac16e94487c, content=<a href='/topic/show?id=d2ea9048398' target=_blank style='color:#2F92EE;'>#西妥昔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90483, encryptionId=d2ea9048398, topicName=西妥昔)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=271a27776763, createdName=chengjn, createdTime=Thu Jan 24 16:28:00 CST 2019, time=2019-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1491832, encodeId=715d14918321b, content=<a href='/topic/show?id=b4f14442346' target=_blank style='color:#2F92EE;'>#头颈部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44423, encryptionId=b4f14442346, topicName=头颈部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b2d8903151, createdName=wshxjq, createdTime=Mon Oct 01 10:28:00 CST 2018, time=2018-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589777, encodeId=cbff1589e774e, content=<a href='/topic/show?id=124d10065220' target=_blank style='color:#2F92EE;'>#颈部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100652, encryptionId=124d10065220, topicName=颈部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c46a17776631, createdName=木头人519, createdTime=Mon Oct 01 10:28:00 CST 2018, time=2018-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=347262, encodeId=f53834e26275, content=放疗技术的改进 现如今放化疗耐药是限制提高局控率降低远转的主要难题 这个基因的发现将有助于耐药机制的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c2ac2452729, createdName=123faa6dm71暂无昵称, createdTime=Sat Sep 29 21:27:47 CST 2018, time=2018-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=347260, encodeId=4fdd34e260db, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4mzqK7XHyH86ToibWNdzamnZozW6yiceXFib4QHq1lCOia34v7bgwXUIH1Rdnoqia2y6ibLX156v1xmicZw/0, createdBy=15891613430, createdName=xuexin53, createdTime=Sat Sep 29 21:11:23 CST 2018, time=2018-09-29, status=1, ipAttribution=)]
    2018-09-29 xuexin53

    学习

    0

相关资讯

2018 台湾共识建议：接受同步放化疗的头颈部肿瘤患者的营养干预

由于其解剖学位置，头颈部肿瘤患者经常在确诊时已经存在吞咽困难和营养不良，并且这些情况通常会在放疗后加剧。因此临床急需该类患者的营养干预共识，本文由来自台湾的多学科专家小组共同制定，主要内容涉及营养不良的影响，预防性管饲的作用以及接受放化疗患者口服营养补充剂的益处等。

CLIN CANCER RES：Tim-3+ Treg细胞在头颈部肿瘤患者中发挥抑制作用

调节性T（Treg）细胞是肿瘤浸润淋巴细胞（TIL）中的重要抑制细胞。Treg细胞表达免疫检查点受体PD-1，既往报道表达PD-1的Treg为抑制功能较低的"耗竭性"Treg。T细胞免疫球蛋白粘蛋白（Tim）-3是Th1免疫的负性调节因子，大量TIL Tregs均有表达，但Tim-3 + Tregs的功能目前仍不清楚。CLIN CANCER RES近期发表了一篇文章研究这一问题。

3D打印非共面坐标模板辅助CT引导放射性125I粒子植入治疗头颈部肿瘤专家共识

头颈部癌占全身恶性肿瘤的30%，治疗以手术为主。局部晚期或无法手术切除时以放射治疗联合化疗为主。手术、放疗后局部、区域复发仍是主要失败原因，复发后挽救治疗目前尚无理想的方法；放射性粒子植人治疗已成为早期前列腺癌标准治疗手段之一。前列腺癌粒子植入治疗是经直肠超声引导联合会阴部模板辅助，实现粒子在前列腺内空间合理分布，可确保粒子植入治疗与术前计划完全一致。

2018 临床实践指南：头颈部肿瘤中三叉神经 (V) 及其分支轮廓

三叉神经 (V)是头颈部肿瘤的主要转移途径，当前只有有限的数据可用于其精确边界轮廓。本文的主要目的是指导头颈部肿瘤三叉神经 (V)轮廓确定。

NCCN临床实践指南：头颈部肿瘤（2018.V2）

2018年6月，美国国家综合癌症网络(NCCN)发布了头颈部肿瘤指南2018年第2版，指南主要内容涉及： 指南更新摘要 多学科团队支持服务 唇癌 口腔癌 咽部肿瘤 下咽癌 鼻咽癌 声门癌 声门上喉头癌 筛窦肿瘤 上颌窦肿瘤 晚期头颈部癌 复发性/顽固性头颈部肿瘤 原发性肿瘤 涎腺肿瘤 黏膜黑素瘤 随访建议 手术治疗原则 放射治疗 系统治疗原则 支持性治疗营养原则 口腔科评估和管理 分期

Radiology：氨基酸质子转移MRI在头颈部肿瘤的价值

本研究旨在评价氨基酸质子转移（APT）成像在显示头颈部肿瘤的价值，将结果发表在radiology上。